Ping An Biomedical Co., Ltd. PASW
- Market cap
- $16.2M
- P/E
- —
Follow PASW
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 0.35 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 5.40 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 7 | 7 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 2 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 12 | 5 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 6.18% | 2.78% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (0.78%) | (43.00%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.69 | 0.26 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.01) | (0.10) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.12 | (0.05) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.12 | (0.05) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.06) | 0.34 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 18 | 18 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | 2 | (1) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | 2 | (1) |
FCF
|
|||
| — | — | — | — | — | — | — | — | (1) | 6 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 1 | (4) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (1) | 6 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (20.35%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (0.04%) | (49.29%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (67.61%) |
ROE
|
|||
Ping An Biomedical Co., Ltd. peers in Textile Manufacturing
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DXYN The Dixie Group, Inc. | $13.8M | 0.0× | Compare |
| SMJF SMJ International Holdings Inc. | $42.5M | — | Compare |
| CULP Culp, Inc. | $44.7M | 0.0× | Compare |
| UFI Unifi, Inc. | $122.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AIN Albany International Corporation | $1.7B | 0.0× | Compare |
Ping An Biomedical Co., Ltd. (PASW) key facts
- Ping An Biomedical Co., Ltd. (PASW) is a Textile Manufacturing company in the Consumer Cyclical sector, listed on Nasdaq.
- Ping An Biomedical Co., Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $4.8 million, down 61.6% from fiscal 2024.
- Ping An Biomedical Co., Ltd. reported a net loss of $1.8 million, or a loss of $0.10 per share, for fiscal 2025.
- As of September 25, 2026, PASW traded at $0.13, a market capitalization of $16.2 million.
- Return on equity was −67.6% and debt-to-equity 0.13.
Ping An Biomedical Co., Ltd. (PASW) Latest News
22 Jul
Ping An Biomedical signs strategic cooperation agreement with Yuan Sheng Mei Yan targeting RMB 500 million in sales over three years. Partnership sets RMB 500 million sales target over three years that may support revenue growth.
Majestic Ideal Holdings Limited (Nasdaq: MJID) has closed its initial public offering of 2,500,000 ordinary shares at $6.00 per share, raising $15.0 million in gross proceeds. The shares began trading on July 18, 2025. Proceeds will be used for raw material procurement, customer development, efficiency enhancement, and general working capital. The underwriters have a 45-day option to purchase an additional 375,000 shares. The offering was conducted under the SEC's Registration Statement on Form F-1, effective June 30, 2025. The IPO and subsequent funding are expected to moderately influence the company's financial performance and market positioning.
19 Mar
Ping An Biomedical Co., Ltd. (PASW) shareholders passed all resolutions at the annual general meeting, clearing the path for restructured share capital. Passing all AGM resolutions enables share capital restructuring, a significant strategic move that could alter the company's trajectory and investor sentiment.
9 Jan
Ping An Biomedical Co., Ltd. has announced a strategic investment in Future Biotechnology Group aimed at fostering collaborative development within the biopharmaceutical industry. This partnership is expected to enhance innovation and accelerate advancements in biotechnology, positioning both companies for growth in a competitive market. The strategic investment is likely to significantly impact future performance and market positioning in the biopharmaceutical sector.
Ping An Biomedical Co., Ltd. has secured a strategic investment from a leading industry capital firm, which is expected to accelerate its growth in biopharmaceutical innovation. This investment will enhance the company's capabilities and position in the competitive biopharmaceutical market. The strategic investment is likely to significantly impact future growth and market positioning in the biopharmaceutical sector.
28 Nov
Ping An Biomedical Co., Ltd. has received a deficiency letter from Nasdaq regarding its minimum bid price. The company is now required to regain compliance with the exchange's listing standards within a specified timeframe. Failure to do so may result in delisting from Nasdaq. The company is evaluating its options to address this issue and maintain its listing status. Receiving a deficiency letter from Nasdaq may affect investor sentiment and compliance efforts, but it does not fundamentally alter the company's core operations.
12 Sep
Majestic Ideal Holdings Ltd. (MJID) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
Majestic Ideal Holdings Ltd. has received approval for a name change to 'Ping An Biomedical Co., Ltd.' during an Extraordinary General Meeting. This change reflects a strategic shift in the company's focus and branding. The name change indicates a potential shift in business strategy that may moderately influence market perception and operations.
18 Jul
LQR House (YHC) announced plans to expand its focus by integrating cryptocurrency into its operations, signaling a strategic shift that could impact its market positioning. The integration of cryptocurrency may moderately influence LQR House's competitive positioning and market sentiment.
17 Jul
Majestic Ideal Holdings Limited announced the pricing of its initial public offering of 2,500,000 ordinary shares at $6.00 per share, set to begin trading on Nasdaq under the symbol 'MJID' on July 18, 2025. The offering is expected to close on July 21, 2025, and proceeds will be used for raw material procurement, customer base expansion, efficiency enhancement, and general working capital. The underwriters have a 45-day option to purchase an additional 375,000 shares. The offering is conducted under the SEC's effective Registration Statement on Form F-1. The IPO and planned use of proceeds indicate significant strategic moves that could enhance the company's market position and investor sentiment.